Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire - Tue Jun 30, 7:00AM CDT

—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...

STOK : 31.38 (-4.42%)
BIIB : 199.15 (+0.12%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Tue Jun 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.38 (-4.42%)
Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire - Thu May 28, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.38 (-4.42%)
BIIB : 199.15 (+0.12%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Mon May 18, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.38 (-4.42%)
MarketBeat.com
Stoke Therapeutics Q1 Earnings Call Highlights MarketBeat - Fri May 8, 11:07PM CDT

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label...

STOK : 31.38 (-4.42%)
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates Business Wire - Thu May 7, 3:01PM CDT

– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the...

STOK : 31.38 (-4.42%)
BIIB : 199.15 (+0.12%)
Stoke Therapeutics' Mounting Losses May Actually Validate Its Platform Better Than a Profit Would Barchart - Wed May 6, 4:32PM CDT

Barchart Research What to Expect from STOK Earnings STOK Generated May 6, 2026 Current Price $33.28 EPS Estimate $$-0.80 Consensus Rating Strong Buy Average Move 6.37% Stoke Therapeutics' Mounting Losses...

STOK : 31.38 (-4.42%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates Business Wire - Thu Apr 30, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.38 (-4.42%)
BIIB : 199.15 (+0.12%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Thu Apr 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.38 (-4.42%)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 8, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 31.38 (-4.42%)
BIIB : 199.15 (+0.12%)

Barchart Exclusives

Intel Future Price Hikes Send Huge Demand Signal to Wall Street Barchart - Sat Jul 11, 2:30PM CDT
Intel is raising chip prices as server CPU demand outpaces supply, and Wall Street sees the move as proof of a much bigger AI-driven boom ahead. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.